Sore, stiff joints are more than just a nuisance. When pain flares up, it can sometimes make even simple tasks like driving or writing challenging. But what you might not know is that if your joint ...

Psoriasis is a relapsing chronic inflammatory condition of the skin, which manifests itself in other areas such as the synovial membranes and soft tissues around many joints, eyes, heart, and blood ...

Psoriatic arthritis (PsA) is an inflammatory disease marked by its multi-domain involvement, from the peripheral and axial joints, skin and nails, enthesitis, eyes, and digits. 1 This complex ...

There is no one defining symptom of PsA, and you may experience more than one symptom at once. Early signs can include joint pain and stiffness, along with changes to your fingernails or red, scaly ...

Like many chronic conditions, psoriatic arthritis (PsA) isn’t something you manage just once. Your psoriatic arthritis treatment journey might be more of a marathon than a sprint, with a few ...

LOS ANGELES, California — If a patient with psoriasis presents with dactylitis, inflammatory back pain, and/or tendon inflammation, think psoriatic arthritis until proven otherwise. At the annual fall ...

Please provide your email address to receive an email when new articles are posted on . Patients with psoriatic arthritis who received 30 mg and 60 mg daily doses of brepocitinib had significantly ...

THOUSAND OAKS, Calif. and LONDON, June 11, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with ...

(RTTNews) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or SKYRIZI in ...

Treating psoriatic arthritis (PsA) isn't like treating strep throat. You don't just take one medicine for a few days and feel better. PsA is a complex, chronic disease that stays with you and affects ...

(RTTNews) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or SKYRIZI in ...